Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Sunday, April 26

Benefits of IVIG in Pediatric Acute-Onset Neuropsychiatric Syndrome (2411)

Isaac Melamed, Roger Kobayashi, Maeve O’Connor, Ai Lan Kobayashi, Andrew Schechterman, Melinda Heffron, Sharon Canterberry, Holly Miranda, Nazia Rashid
First published April 14, 2020,
Isaac Melamed
1IMMUNOe Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Kobayashi
2UCLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maeve O’Connor
3Allergy, Asthma & Immunology Relief
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ai Lan Kobayashi
4Midlands Pediatrics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Schechterman
5Colorado Neurogeriatrics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melinda Heffron
1IMMUNOe Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Canterberry
4Midlands Pediatrics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Miranda
1IMMUNOe Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nazia Rashid
6Dunwoody Consulting
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Benefits of IVIG in Pediatric Acute-Onset Neuropsychiatric Syndrome (2411)
Isaac Melamed, Roger Kobayashi, Maeve O’Connor, Ai Lan Kobayashi, Andrew Schechterman, Melinda Heffron, Sharon Canterberry, Holly Miranda, Nazia Rashid
Neurology Apr 2020, 94 (15 Supplement) 2411;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To test the hypothesis that pediatric acute-onset neuropsychiatric syndrome (PANS) is related to an autoimmune dysfunction, a multi-site study explored intravenous immunoglobulin (IVIG)[Octagam 5%] for treatment.

Background: PANS is a clinical diagnosis in children who have an acute manifestation of varied neuropsychiatric symptoms, including obsessive compulsive disorder (OCD), eating disorders, tics, anxiety, irritability, and problems with attention/concentration. PANS may develop as a result of a post-infectious syndrome. Our hypothesis is that PANS may represent a new form of post-infectious autoimmunity, through molecular mimicry, suggesting a potential mechanism by which the disorder evolves.

Design/Methods: The primary endpoint was evaluation of IVIG efficacy over a period of 6 months/infusions based on mean changes in psychological evaluation scores using 6 validated assessments including the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS). Secondary endpoints included evaluation of presenting immune/autoimmune panels and key potential biomarkers.

Results: The final cohort consisted of 21 subjects (7 per site) with moderate to severe PANS. The mean age was 10.86 years (range: 4–16 years). Results demonstrated statistically significant reductions in symptoms from baseline to end of treatment (infusion 6) in all 6 assessments measured. CY-BOCS results demonstrated statistically significant reductions in obsessive compulsive symptoms, resulting in > 50% improvement sustained for at least 8 weeks after the final infusion and up to 46 weeks in a subset of subjects.

Conclusions: In PANS, which may be associated with an underlying immune dysregulation, IVIG [Octagam 5%] successfully ameliorated psychological symptoms and dysfunction, with sustained benefits for at least 8 weeks, and up to 46 weeks, following the final infusion. In addition, baseline immune and autoimmune profiles demonstrated significant elevations in a majority of subjects, which requires further evaluation, characterization, and study to clarify the potential immune dysfunction by which PANS manifests and progresses.

Disclosure: Dr. Melamed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Octapharma, IMMUNOe. Dr. Melamed has received research support from Octapharma, Pharming Group. Dr. Kobayashi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Octapharma, Shire/Takeda, UCLA. Dr. O’Connor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Octapharma, Allergy, Asthma & Immunology Relief. Dr. O’Connor has received research support from Octapharma. Dr. Kobayashi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Octapharma, Midlands Pediatrics. Dr. Kobayashi has received research support from Octapharma. Dr. Schechterman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Colorado Neurogeriatrics. Dr. Heffron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with IMMUNOe. Dr. Canterberry has nothing to disclose. Dr. Miranda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with IMMUNOe. Dr. Rashid has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dunwoody Consulting.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise